Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 7/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.57 |
| ▸ | HTR3B | O95264 | 4/20 | 0.57 |
| ▸ | HTR3A | P46098 | 4/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5570604 | 0.82 | ADRB1 (0.77) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Tert-Butyl Formate SCHEMBL27908683 | 0.82 | ADRB1 (0.44) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6956744 | 0.82 | KDM4E (0.63) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL231077 | 0.82 | KDM4E (0.63) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL578312 | 0.81 | AKR1C3 (0.53) | AKR1C3ALDH1A1KDM4ELMNAUSP2 | |
| SCHEMBL28704374 | 0.81 | AKR1C3 (0.53) | AKR1C3ALDH1A1KDM4ELMNADRD2 | |
| Hydrochloric Acid SCHEMBL23303443 | 0.80 | KDM4E (0.61) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL15817965 | 0.80 | ADRB1 (0.57) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL376202 | 0.80 | KDM4E (0.61) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL14661682 | 0.80 | ADRB1 (0.57) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025051640-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA | LightOx Limited (GB) | 2025-03-13 | — | — | WO | disclosed |
| US-8912200-B2 | Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-16 | — | — | US | disclosed |
| US-20140194406-A1 | ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-10 | — | — | US | disclosed |
| EP-2736514-A1 | ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2014-06-04 | — | — | EP | disclosed |
| US-8487109-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI (FR) | 2013-07-16 | — | — | US | disclosed |
| EP-2556071-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (CA) | 2013-02-13 | — | — | EP | disclosed |
| WO-2013014039-A1 | ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-31 | — | — | WO | disclosed |
| WO-2011123946-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-13 | — | — | WO | disclosed |
| EP-2176203-B1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | SANOFI SA (FR) | 2011-08-10 | — | — | EP | disclosed |
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| EP-2176203-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | Sanofi-Aventis (FR) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009003589-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | disclosed |
| US-4720567-A | Novel diacetylenic and polydiacetylenic compositions | HOECHST CELANESE CORPORATION (US) | 1988-01-19 | — | — | US | disclosed |
| US-4711532-A | Novel diacetylenic and polydiacetylenic compositions | HOECHST CELANESE CORPORATION (US) | 1987-12-08 | — | — | US | disclosed |
| EP-0243807-A2 | Novel diacetylenic and polydiacetylenic compositions | CELANESE CORPORATION (US) | 1987-11-04 | — | — | EP | disclosed |
| US-4703096-A | Novel diacetylenic and polydiacetylenic compositions | CELANESE CORPORATION (US) | 1987-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194406-A1 | ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS | JAK2, JAK1, SRC | ADRB1 3748/4885HTR3E 2173/4885HTR3B 3038/4885 |
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | TYR, ALK, TYRO3 | ADRB1 578/4885HTR3E 1895/4885HTR3B 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.